Institutional investors hold a majority ownership of ALXN through the 98.74% of the outstanding shares that they control. This interest is also higher than at almost any other company in the Biotechnology industry. Last, during the quarter ended March 2015, these large investors purchased a net $717.8 thousand shares.
Mutual fund holders
Largest Quarterly Institutional Transactions
Latest Institutional Activity
T. ROWE PRICE ASSOCIATES, INC. Bought 1.9 Million shares of Alexion Pharmaceuticals I...